Kouki Okita
Overview
Explore the profile of Kouki Okita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakano T, Okita K, Okazaki S, Yoshimoto S, Masuko S, Yagi H, et al.
FEBS Open Bio
. 2025 Jan;
PMID: 39757718
Effective therapies have yet to be established for pancreatic ductal adenocarcinomas (PDAC) even though it is the most aggressive cancer. In the present study, PDAC was analyzed using novel rat...
2.
Yamasaki A, Maruyama-Takahashi K, Nishida K, Okazaki S, Okita K, Akiyama Y, et al.
Genes Cells
. 2023 Feb;
28(5):374-382.
PMID: 36811310
Human epidermal growth factor receptor (HER) family proteins are currently major targets of therapeutic monoclonal antibodies against various epithelial cancers. However, the resistance of cancer cells to HER family-targeted therapies,...
3.
Yamasaki A, Miyake R, Hara Y, Okuno H, Imaida T, Okita K, et al.
Cancer Med
. 2023 Feb;
12(8):9684-9696.
PMID: 36751113
Background: Colorectal cancer (CRC) is the most common malignancy in the world, and novel molecular targeted therapies for CRC have been vigorously pursued. We searched for novel combination therapies based...
4.
Okita K, Imai K, Kato K, Sugiura R, Endo Y, Masuko K, et al.
Biochem Biophys Res Commun
. 2021 Sep;
576:59-65.
PMID: 34482024
HER1-and HER2-targeted drugs are effective in cancer therapy, especially against lung, breast and colon malignancies; however, resistance of cancer cells to HER1-and HER2-targeted therapies is becoming a serious problem. The...
5.
Okita K, Hara Y, Okura H, Hayashi H, Sasaki Y, Masuko S, et al.
Cancer Sci
. 2020 Nov;
112(2):563-574.
PMID: 33211385
Copy number alterations detected by comparative genomic hybridization (CGH) can lead to the identification of novel cancer-related genes. We analyzed chromosomal aberrations in a set of 100 human primary colorectal...
6.
Okita K, Okazaki S, Uejima S, Yamada E, Kaminaka H, Kondo M, et al.
Oncotarget
. 2020 Feb;
11(1):31-45.
PMID: 32002122
Resistance of progressive cancers against chemotherapy is a serious clinical problem. In this context, human epidermal growth factor receptor 3 (HER3) can play important roles in drug resistance to HER1-...
7.
Piulats J, Kondo J, Endo H, Ono H, Hagihara T, Okuyama H, et al.
Oncotarget
. 2018 Apr;
9(22):15968-15983.
PMID: 29662620
Individual and small clusters of cancer cells may detach from the edges of a main tumor and invade vessels, which can act as the origin of metastasis; however, the mechanism...
8.
Yuan Q, Furukawa T, Tashiro T, Okita K, Jin Z, Aung W, et al.
PLoS One
. 2015 Nov;
10(11):e0143076.
PMID: 26571416
HER3 is overexpressed in various carcinomas including colorectal cancer (CRC), which is associated with poor prognosis, and is involved in the development of therapy resistance. Thus, an in vivo imaging...
9.
Kinoshita T, Yoshida I, Nakae S, Okita K, Gouda M, Matsubara M, et al.
Biochem Biophys Res Commun
. 2008 Nov;
377(4):1123-7.
PMID: 18983981
Extracellular signal-regulated kinase (ERK) is a member of the MAP kinase family, and can regulate several cellular responses. The isoforms ERK1 and ERK2 have markedly similar amino acid sequences, but...
10.
Kinoshita E, Kinoshita-Kikuta E, Matsubara M, Yamada S, Nakamura H, Shiro Y, et al.
Proteomics
. 2008 Jul;
8(15):2994-3003.
PMID: 18615432
Herein, we demonstrate the separation of phosphoprotein isotypes having the same number of phosphate groups using phosphate-affinity SDS-PAGE. The phosphate-affinity site is a polyacrylamide-bound Phos-tag that enables the mobility shift...